stemmacs chir99021 (Miltenyi Biotec)
Miltenyi Biotec is a verified supplier 
Miltenyi Biotec manufactures this product 
96
Structured Review
Miltenyi Biotec
stemmacs chir99021
Stemmacs Chir99021, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 73 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chir99021/StemMACS+CHIR99021/pmc13369415-47-15-19
Average 96 stars, based on 73 article reviews
Stemmacs Chir99021, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 73 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/chir99021/StemMACS+CHIR99021/pmc13369415-47-15-19
Average 96 stars, based on 73 article reviews
stemmacs chir99021 - by Bioz Stars,
2026-09
96/100 stars
Images
1) Product Images from "Synergistic Wnt/BMP Co-activation accelerates osteogenic differentiation of human pluripotent stem cells via paraxial mesoderm induction"
Article Title: Synergistic Wnt/BMP Co-activation accelerates osteogenic differentiation of human pluripotent stem cells via paraxial mesoderm induction
Journal: Journal of Tissue Engineering
doi: 10.1177/20417314261468879
Figure Legend Snippet: A schematic showing BMP4-mediated osteogenesis maturation through CHIR-induced mesodermal differentiation through Wnt activation and BMP signaling, efficient osteoblast differentiation with hiPSCs is synergistically promoted through Wnt/BMP signaling. hiPSC, Human induced pluripotent stem cells; CHIR, CHIR99021; BMP4, Bone morphogenetic protein 4.
Techniques Used: Activation Assay
Figure Legend Snippet: Coactivation of Wnt/BMP signaling specifies the differentiation of hiPSCs to a paraxial mesoderm. (a) A schematic diagram of the protocol of mesoderm according to the differentiation period. (b-e) Graphs of mRNA expression of MSGN1 , TBX6 , ISL1 , and NKX2.5 in mesenchymal-induced cultures (n=3). (f-g) Graphs of MSGN1 and RUNX2 mRNA expression according to the concentrations of BMP2 and BMP4 (n=3 and 5). (h-i) Graphs of TBX6 and RUNX2 mRNA expression for BMP4 (n=5). Groups: PM, Pluripotent stem cell Medium; MM, Mesoderm differentiation Medium; AC, CHIR; ACB, CHIR+BMP4. hiPSC, Human induced pluripotent stem cells; CHIR, CHIR99021; BMP2, Bone morphogenetic protein 2; BMP4, Bone morphogenetic protein 4. All data represent mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
Techniques Used: Expressing
Figure Legend Snippet: Total RNA Sequencing. (a) Transcription profile of 75 genes relevant to osteogenesis for hiPSC cultured for 2 days in mesoderm differentiation medium. Relative expression: red (high) and blue (low) (b) Heatmaps for markers related to osteogenesis. Relative expression: red (high) and green (low) (c) Gene ontology enrichment dot plot. Relative expression: red (high) and big dot (high). Groups: AC, CHIR; ACB, CHIR+BMP4. hiPSC, Human induced pluripotent stem cells.
Techniques Used: RNA Sequencing, Cell Culture, Expressing
Figure Legend Snippet: Limited activation of the BMP signaling in the mesoderm period promotes the maturation of osteoblasts. (a) Schematic protocol for osteoblast differentiation via mesoderm. (b) Optical images of hiPSC according to differentiation (X40). (c-d) Graphs of mRNA gene expression of RUNX2 and COL1 according to BMP4 concentration. (e-g) Graphs of mRNA expression of COL1 , ON , and OCN . ON: osteonectin, OCN: osteocalcin. Scale bar: 500 μm. Groups: DAG, Dorsal axial mesoderm; APEL, Albumin, polyvinyl alcohol, essential lipids; AC, CHIR; ACB, CHIR+BMP4. hiPSC, Human induced pluripotent stem cells; CHIR, CHIR99021; BMP4, Bone morphogenetic protein 4. All data represent mean ± SD (n=5). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
Techniques Used: Activation Assay, Gene Expression, Concentration Assay, Expressing
Figure Legend Snippet: Coactivation of Wnt/BMP signaling facilitates the maturation of osteoblasts. (a) Optical images of hiPSC for 9 days with or without BMP4 (X40). (b) ARS images of hiPSC on day 9 (X40). (c) Quantification graph of ARS absorbance at 540 nm wavelength (n=4). (d) Von Kossa images of hiPSC on day 9 (X100). (e) Quantification graph of Von Kossa + area (n=6). (f) Immunofluorescence staining images for hiPSC after osteogenic differentiation (X200). (g) Quantification graph of RUNX2 + and COL1 + area (n=3). Scale bars: (a-b) 500 μm, (d) 200 μm, (f) 100 μm. Groups: AC, CHIR; ACB, CHIR+BMP4. All data represent mean ± SD. *P < 0.05, **P < 0.01, and ****P < 0.0001. The symbol * indicates comparisons with the AC group.
Techniques Used: Immunofluorescence, Staining
Figure Legend Snippet: Differentiation of bone formation in vivo . (a) A schematic diagram of in vivo experiments. (b) Graph of mouse weight change. (c) Images of scaffold incubated for 6 weeks in vivo . (d) 3D rendering images for micro-CT image of scaffold. (e) Images of H&E on scaffold (X200). (f) Images of von Kossa staining on the scaffold (X200). Scale bars: (c) 50 mm, (d) 5 mm, (e-f) 100 μm. Groups: Control, no treatment; Scaffold, scaffold only; BMSC, Scaffold+BMSC; AC, Scaffold+BMSC+CHIR; ACB, Scaffold+BMSC+CHIR+BMP4. All data represent mean ± SD (n=3). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. The symbol * indicates comparisons with the Scaffold group.
Techniques Used: In Vivo, Incubation, Micro-CT, Staining, Control
Related Articles
other:Article Title: Method and kit for characterizing dopaminergic progenitor cells obtained by differentiating pluripotent stem cells Article Snippet: From d0 to d9 the following neuralization and patterning factors were Article Title: Method and kit for characterizing dopaminergic progenitor cells obtained by differentiating pluripotent stem cells Article Snippet: From d0 to d9 the following neuralization and patterning factors were present: Article Title: EpiFlow: multidimensional single-cell epigenetic profiling by spectral flow cytometry Article Snippet: To obtain the naive-pluripotent state, 1 μM Article Title: NELFA supports naïve pluripotency and drives 8C-like state in human embryonic stem cells Article Snippet: ME induction medium contained aRB27 medium supplemented with 100 ng/ml ACTIVIN A (Peprotech, 338-AC), 3 μM Article Title: Method and kit for characterizing dopaminergic progenitor cells obtained by differentiating pluripotent stem cells Article Snippet: From d0 to d9 the following neuralization and patterning factors were Article Title: Slow RNAPII elongation enhances naive pluripotency rewiring while maintaining high replication fork speed Article Snippet: The naive pluripotency state was obtained by adding 1 μM Article Title: The Epigenetic Factor PHF13 Governs Trophoblast Stemness and Differentiation Article Snippet: TS cell medium consisted of basal medium DMEM/F-12, GlutaMAX (Thermo Fisher, #10565042) supplemented with 0.3% bovine serum albumin (BSA; Sigma, #A9576-50ML), 0.2% fetal bovine serum (FBS; Thermo Fisher, #16141079), 1% ITS-X supplement (Thermo Fisher, #51500056), 0.1 mM 2-mercaptoethanol (Thermo Fisher, #31350010), 0.5% penicillin–streptomycin (Thermo Fisher, #15140122), 1.5 μg/ml L-ascorbic acid (Sigma, #A4544-25G), 50 ng/ml epidermal growth factor (EGF; PeproTech, AF-100-15), 1 μM SB431542 (Selleck Chemicals, #S1067), 0.5 μM A83-01 (Sigma, #SML0788-5MG), 0.8 mM valproic acid (Sigma, #P4543-10G), 2 μM Article Title: S100A10-ANXA2 tetramer inhibition hampers hepatic stellate cell activation in human MASLD organoids. Article Snippet: The medium was switched to advanced DMEM/F12 (Gibco, 12634010) from day 4 to day 6, supplemented with 0.1 mM Hepes, GlutaMax (Gibco, 35050038), 1× B27 (Gibco, 17504044), 1× N2 (Gibco, 17502048), 1x Gentamycin/Amphotericin (Gibco, R01510), 500 ng/mL fibroblast growth factor 4 (FGF4, PeproTech, 100-31), 3 μM |